Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ryousei Sasaki"'
Autor:
Kazuki, Kiyohara, Norifumi, Sugawara, Takahiro, Maeta, Shinri, Miyajima, Motoki, Takano, Masao, Nishiya, Maki, Nishiya, Ryousei, Sasaki, Yoshiaki, Okano, Satsuki, Kamihara, Shugo, Kowata, Tatsuo, Oyake, Shigeki, Ito
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 62(10)
A 67-year-old woman diagnosed with adult T-cell leukemia/lymphoma received an induction chemotherapy and showed a partial response. She then underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical sibling donor. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d84e24b6b2d40e9081a3bc1115336d74
https://pubmed.ncbi.nlm.nih.gov/34732623
https://pubmed.ncbi.nlm.nih.gov/34732623
Publikováno v:
Leukemia Research. 39:1473-1479
Adult T-cell leukemia (ATL) is an aggressive malignancy of peripheral T cells infected with human T-cell leukemia virus type 1 (HTLV-1). The prognosis of patients with aggressive ATL remains poor because ATL cells acquire resistance to conventional c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abc6799799597d75fa1793f53f13a70a
https://doi.org/10.1016/j.leukres.2015.10.012
https://doi.org/10.1016/j.leukres.2015.10.012
Publikováno v:
Leukemia research. 37(12)
Adult T-cell leukemia (ATL) is an aggressive malignancy of peripheral T cells infected with human T-cell leukemia virus type 1 (HTLV-1). The prognosis of patients with aggressive ATL remains poor because ATL cells acquire resistance to conventional c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2bee02ac6e6fb396e69f2b09d7e3b0
https://pubmed.ncbi.nlm.nih.gov/24090995
https://pubmed.ncbi.nlm.nih.gov/24090995
Autor:
Yoji Ishida, Kazunori Murai, Wataru Izumita, Norifumi Sugawara, Yukiteru Fujishima, Maki Asahi, Ryousei Sasaki, Takahiro Mine, Yasuhiko Tsukushi, Yuka Fujisawa, Ichiro Hanamura, Shugo Kowata, Yusei Aoki, Yoshiaki Okano, Shigeki Ito, Yuzo Suzuki, Tatsuo Oyake
Publikováno v:
Blood. 128:1607-1607
Background: Invasive fungal infections (IFIs) incur significant morbidity and mortality in neutropenic patients with hematological malignancies (HEM) after chemotherapy. The risk for these infections is related to the intensity and duration of neutro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fea70ef780afd4915da16d8547e6160
https://doi.org/10.1182/blood.v128.22.1607.1607
https://doi.org/10.1182/blood.v128.22.1607.1607
Autor:
Shigeki Ito, Yuzo Suzuki, Yusei Aoki, Tatsuo Oyake, Yoji Ishida, Yukiteru Fujishima, Ryousei Sasaki, Maki Asahi, Yoshiaki Okano, Shugo Kowata, Tadashi Shimoyama
Publikováno v:
Open Journal of Hematology. 5:1
The European Myeloma Network (EMN) has recently proposed an algorithm for the optimal starting dose and dose modification of antimyeloma drugs for elderly or unfit patients with multiple myeloma. However, the feasibility of this algorithm remains unc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec32ba438053d20f8c09ec9e2ef795d6
https://doi.org/10.13055/ojhmt_5_1_9.141027
https://doi.org/10.13055/ojhmt_5_1_9.141027
Publikováno v:
Blood. 122:1667-1667
Survivin is a member of the inhibitor of apoptosis protein (IAP) family with its dual roles in mitosis and apoptosis, and emerges as an attractive target for cancer therapy. Recent reports have demonstrated that survivin overexpression is associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e83dfef083780ef1dbf140261156d28b
https://doi.org/10.1182/blood.v122.21.1667.1667
https://doi.org/10.1182/blood.v122.21.1667.1667
Autor:
Ryousei Sasaki, Yukiteru Fujishima, Takahiro Mine, Maki Asahi, Shigeki Ito, Yuzo Suzuki, Tatsuo Oyake, T. Shimoyama, Yoji Ishida, Kazunori Murai
Publikováno v:
Annals of Oncology. 24:ix49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed71cd1cbfe5c960071ea417557cadeb
https://doi.org/10.1093/annonc/mdt459.83
https://doi.org/10.1093/annonc/mdt459.83
Autor:
Yukiteru Fujishima, Kazunori Murai, Takahiro Mine, Yoji Ishida, Takeshi Sugawara, Ryousei Sasaki, Shigeki Ito, Tatsuo Oyake
Publikováno v:
Annals of Oncology. 23:xi84
Background Lenalidomide (Len) is effective for relapsed and refractory multiple myeloma (RRMM). Recently, the European Myeloma Network (WMN) proposed the optimal starting dose of anti-myeloma drugs for elderly myeloma patients according to patient ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc5a9868c24fc068bd295fae8b4d83d4
https://doi.org/10.1016/s0923-7534(20)32192-x
https://doi.org/10.1016/s0923-7534(20)32192-x